Guardant Health, Inc. - Common Stock (GH)
150.87
-2.56 (-1.67%)
NASDAQ · Last Trade: Nov 7th, 2:06 AM EST
News & Press Releases
Guardant Health (GH) Q3 2026 Earnings Call Transcriptfool.com
Shield cost per test beat its target early while screening guidance moved higher.
Via The Motley Fool · November 6, 2026
GH Q3 2026 deep dive: new product launches and coverage wins drive growth, but market cautious on profitability
Diagnostics company Guardant Health (NASDAQ:GH) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 36.1% year on year to $36...
Via StockStory · November 6, 2026
1 healthcare stock to research further and 2 we avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via StockStory · November 5, 2026
Guardant Health Inc (NASDAQ:GH) Falls 12% Despite In-Line Q3 Revenue as Guidance Disappointschartmill.com
Via Chartmill · November 5, 2026
What Guardant Health (GH) Said on Its Q3 Earnings Callmarketbeat.com
Guardant Health (NASDAQ:GH) raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based cancer screening test.
The company reported revenue of $361 million for the quarter ended Sept. 30,
Via MarketBeat · November 5, 2026
Guardant Health’s (NASDAQ:GH) Q3 2026 sales beat estimates but stock drops 10.2%
Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 36.1% year on year to $361 million. The c...
Via StockStory · November 5, 2026
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026.
By Guardant Health, Inc. · Via Business Wire · November 5, 2026
Guardant Health earnings: what to look for from GH
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings this Thursday after the bell. Here’s what to expect. Guardant Health beat analysts...
Via StockStory · November 3, 2026
Kevin Sayer Joins Guardant Health Board of Directors
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology.
By Guardant Health, Inc. · Via Business Wire · November 3, 2026
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for Shield™, the leading blood test for colorectal cancer (CRC) detection and first to receive FDA approval for primary CRC screening, for its achievements in expanding patient choice and increasing screening participation for CRC.
By Guardant Health, Inc. · Via Business Wire · November 3, 2026
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance coverage for colorectal cancer screening to reflect the latest American Cancer Society (ACS) and National Comprehensive Cancer Center (NCCN) guidelines, ensuring no cost-sharing for about 2 million Pennsylvanians of screening-eligible age.1
By Guardant Health, Inc. · Via Business Wire · October 29, 2026
3 Reasons GH is risky and 1 stock to buy instead
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 93.5%, hitting $171.24. This was partly due to its solid qu...
Via StockStory · October 26, 2026
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.
By Guardant Health, Inc. · Via Business Wire · October 20, 2026
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winningmarketbeat.com
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Via MarketBeat · October 19, 2026
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Tennessee.
By Guardant Health, Inc. · Via Business Wire · October 15, 2026
3 of Wall Street’s Favorite Stocks That Fall Short
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via StockStory · October 15, 2026
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist. Approval in Europe reinforces Guardant Health's commitment to enabling practice-changing ongoing monitoring across the world's largest healthcare markets.
By Guardant Health, Inc. · Via Business Wire · October 8, 2026
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
By Guardant Health, Inc. · Via Business Wire · October 8, 2026
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients with resected stage II–III melanoma.
By Guardant Health, Inc. · Via Business Wire · October 5, 2026
3 Cash-Burning Stocks with Questionable Fundamentals
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...
Via StockStory · October 5, 2026
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via StockStory · September 29, 2026
1 Unpopular Stock That Should Get More Attention and 2 We Question
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via StockStory · September 21, 2026
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a...
Via StockStory · September 15, 2026
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states.
By Guardant Health, Inc. · Via Business Wire · September 14, 2026
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (WCLC). The conference is hosted by the International Association for the Study of Lung Cancer (IASLC) and will take place September 12–15, 2026, in Seoul, South Korea.
By Guardant Health, Inc. · Via Business Wire · September 9, 2026